A global leader in pharmaceuticals, GSK’s mechanical engineers are responsible for projects ... Find out how our Company Based Registration Scheme can help your organisation. To find out how we can ...

GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, announced a landmark investment ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular ... and discounted stocks. GSK has three segments: Specialty ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

Additionally, GSK has agreed in principle to settle a whistleblower lawsuit brought by Valisure, a laboratory based in Connecticut, with a $70 million payment. Similar to the cases in the other ...

Luxury fashion and lifestyle group Kering, pharma giant GSK and building materials producer Holcim have become the first businesses to set verified science-based targets for nature. The Science-Based ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...

Both GSK and Boehringer sold Zantac at different times during the 30 years that the drug was one of the top-selling antacids in the US. London-based GSK, which developed Zantac in 1983 ...

GSK has agreed to pay up to $2.2 billion to ... The drug companies had sought to keep that testimony out saying it was not based on sound scientific evidence, which would have ended the lawsuits ...

GSK has had another setback in its oncology business ... means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose ...